Franklin Street Advisors Inc. NC Sells 195 Shares of Johnson & Johnson (NYSE:JNJ)

Franklin Street Advisors Inc. NC decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.0% during the fourth quarter, Holdings Channel.com reports. The fund owned 19,220 shares of the company’s stock after selling 195 shares during the quarter. Franklin Street Advisors Inc. NC’s holdings in Johnson & Johnson were worth $2,780,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of JNJ. Bright Futures Wealth Management LLC. lifted its position in shares of Johnson & Johnson by 2.9% in the second quarter. Bright Futures Wealth Management LLC. now owns 3,389 shares of the company’s stock valued at $495,000 after acquiring an additional 94 shares in the last quarter. Sachetta LLC raised its position in shares of Johnson & Johnson by 5.6% during the second quarter. Sachetta LLC now owns 6,797 shares of the company’s stock valued at $1,097,000 after buying an additional 359 shares during the last quarter. Andra AP fonden grew its stake in Johnson & Johnson by 144.0% during the second quarter. Andra AP fonden now owns 461,200 shares of the company’s stock valued at $67,409,000 after acquiring an additional 272,200 shares in the last quarter. Doheny Asset Management CA boosted its holdings in shares of Johnson & Johnson by 65.1% during the 2nd quarter. Doheny Asset Management CA now owns 16,327 shares of the company’s stock valued at $2,296,000 after purchasing an additional 6,437 shares during the last quarter. Finally, First Interstate Bank increased its holdings in shares of Johnson & Johnson by 4.3% in the second quarter. First Interstate Bank now owns 9,260 shares of the company’s stock worth $1,353,000 after purchasing an additional 384 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Trading Up 0.6 %

JNJ stock traded up $0.84 during trading on Friday, hitting $143.11. The company had a trading volume of 3,299,437 shares, compared to its average volume of 7,066,686. The firm has a market capitalization of $344.55 billion, a P/E ratio of 20.71, a PEG ratio of 2.52 and a beta of 0.51. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The company has a 50 day simple moving average of $150.03 and a 200-day simple moving average of $156.04.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The business had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. Johnson & Johnson’s revenue was up 5.2% on a year-over-year basis. During the same period in the previous year, the company posted $2.66 EPS. As a group, research analysts forecast that Johnson & Johnson will post 9.94 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.47%. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

Insider Buying and Selling

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.16% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Royal Bank of Canada increased their target price on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research report on Wednesday, October 16th. Citigroup dropped their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. StockNews.com cut shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Morgan Stanley lifted their price target on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Finally, Wells Fargo & Company raised their price objective on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Seven investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $174.71.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.